{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:14:35Z","timestamp":1789229675550,"version":"build-2803163510"},"reference-count":194,"publisher":"Portland Press Ltd.","issue":"18","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the past two decades, the treatment of cancer has been revolutionised by the highly successful introduction of novel molecular targeted therapies and immunotherapies, including small-molecule kinase inhibitors and monoclonal antibodies that target angiogenesis by inhibiting vascular endothelial growth factor (VEGF) signaling pathways. Despite their anti-angiogenic and anti-cancer benefits, the use of VEGF inhibitors (VEGFi) and other tyrosine kinase inhibitors (TKIs) has been hampered by potent vascular toxicities especially hypertension and thromboembolism. Molecular processes underlying VEGFi-induced vascular toxicities still remain unclear but inhibition of endothelial NO synthase (eNOS), reduced nitric oxide (NO) production, oxidative stress, activation of the endothelin system, and rarefaction have been implicated. However, the pathophysiological mechanisms still remain elusive and there is an urgent need to better understand exactly how anti-angiogenic drugs cause hypertension and other cardiovascular diseases (CVDs). This is especially important because VEGFi are increasingly being used in combination with other anti-cancer dugs, such as immunotherapies (immune checkpoint inhibitors (ICIs)), other TKIs, drugs that inhibit epigenetic processes (histone deacetylase (HDAC) inhibitor) and poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, which may themselves induce cardiovascular injury. Here, we discuss vascular toxicities associated with TKIs, especially VEGFi, and provide an up-to-date overview on molecular mechanisms underlying VEGFi-induced vascular toxicity and cardiovascular sequelae. We also review the vascular effects of VEGFi when used in combination with other modern anti-cancer drugs.<\/jats:p>","DOI":"10.1042\/cs20200308","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T05:27:08Z","timestamp":1601357228000},"page":"2503-2520","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Vascular toxicity associated with anti-angiogenic drugs"],"prefix":"10.1042","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-9263","authenticated-orcid":false,"given":"Karla\u00a0B.","family":"Neves","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto\u00a0C.","family":"Montezano","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian\u00a0N.","family":"Lang","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-0887","authenticated-orcid":false,"given":"Rhian\u00a0M.","family":"Touyz","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"2021113011161361600_B1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/jat.3584","article-title":"Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: past, present and future","volume":"38","author":"Yang","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"2021113011161361600_B2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","article-title":"Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors","volume":"104","author":"Dobbin","year":"2018","journal-title":"Heart"},{"key":"2021113011161361600_B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin. Oncol."},{"key":"2021113011161361600_B4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in england and wales, 1971-2011: a population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"key":"2021113011161361600_B5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"2021113011161361600_B6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021113011161361600_B7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial vegf receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021113011161361600_B8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.tranon.2019.04.022","article-title":"Limitations of anti-angiogenic treatment of tumors","volume":"12","author":"Ribatti","year":"2019","journal-title":"Transl. Oncol."},{"key":"2021113011161361600_B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"133","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"2021113011161361600_B10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10456-012-9327-4","article-title":"Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension","volume":"16","author":"Kruzliak","year":"2013","journal-title":"Angiogenesis"},{"key":"2021113011161361600_B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment","volume":"9","author":"Teleanu","year":"2019","journal-title":"J. Clin. Med."},{"key":"2021113011161361600_B12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"2021113011161361600_B13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/14740338.2015.986092","article-title":"Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy","volume":"14","author":"Bronte","year":"2015","journal-title":"Exp. Opin. Drug Saf."},{"key":"2021113011161361600_B14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/curroncol13050019","article-title":"Receptor tyrosine kinases: role in cancer progression","volume":"13","author":"Sangwan","year":"2006","journal-title":"Curr. Oncol."},{"key":"2021113011161361600_B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumour angiogenesis. Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Eng. J. Med."},{"key":"2021113011161361600_B16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.111.00841","article-title":"Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans","volume":"61","author":"Thijs","year":"2013","journal-title":"Hypertension"},{"key":"2021113011161361600_B17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"key":"2021113011161361600_B18","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.CIR.91.11.2793","article-title":"Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery","volume":"91","author":"Asahara","year":"1995","journal-title":"Circulation"},{"key":"2021113011161361600_B19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1161\/01.CIR.89.5.2183","article-title":"Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs","volume":"89","author":"Banai","year":"1994","journal-title":"Circulation"},{"key":"2021113011161361600_B20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0741-5214(95)70272-5","article-title":"Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor","volume":"21","author":"Bauters","year":"1995","journal-title":"J. Vasc. Surg."},{"key":"2021113011161361600_B21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1006\/bbrc.1995.1194","article-title":"Vascular endothelial growth factor causes endothelial proliferation after vascular injury","volume":"207","author":"Burke","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011161361600_B22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/08977199409000240","article-title":"Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty","volume":"10","author":"Callow","year":"1994","journal-title":"Growth Factors"},{"key":"2021113011161361600_B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the european society of cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011161361600_B24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1097\/HJH.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects","volume":"27","author":"Kappers","year":"2009","journal-title":"J. Hypertens."},{"key":"2021113011161361600_B25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/01.ATV.16.11.1399","article-title":"Expression of vegf receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to vegf","volume":"16","author":"Lindner","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011161361600_B26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vegf signalling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin. Nephrol."},{"key":"2021113011161361600_B27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"2021113011161361600_B28","first-page":"228","article-title":"Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia","volume":"90","author":"Takeshita","year":"1994","journal-title":"Circulation"},{"key":"2021113011161361600_B29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1172\/JCI117018","article-title":"Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model","volume":"93","author":"Takeshita","year":"1994","journal-title":"J. Clin. Invest."},{"key":"2021113011161361600_B30","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1182\/blood.V95.11.3387","article-title":"Up-regulation of vascular endothelial growth factor receptor flt-1 after endothelial denudation: role of transcription factor egr-1","volume":"95","author":"Vidal","year":"2000","journal-title":"Blood"},{"key":"2021113011161361600_B31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1078-5884(98)80180-9","article-title":"Vascular endothelial growth factor (vegf) expression during arterial repair in the pig","volume":"15","author":"Wysocki","year":"1998","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"2021113011161361600_B32","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021113011161361600_B33","doi-asserted-by":"publisher","first-page":"725410","DOI":"10.1155\/2013\/725410","article-title":"Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment","volume":"2013","author":"Ahmadieh","year":"2013","journal-title":"Biomed Res. Int."},{"key":"2021113011161361600_B34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev."},{"key":"2021113011161361600_B35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ctrv.2013.11.009","article-title":"Antiangiogenesis beyond vegf inhibition: a journey from antiangiogeneic single-target to broad-specturm agents","volume":"40","author":"Limaverde-Sousa","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"2021113011161361600_B36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of vegf and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"2021113011161361600_B37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni1013","article-title":"Vascular endothelial growth factor c is required for sprouting of the first lymphatic vessels from embryonic veins","volume":"5","author":"Karkkainen","year":"2004","journal-title":"Nat. Immunol."},{"key":"2021113011161361600_B38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12192-012-0331-9","article-title":"Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity","volume":"17","author":"Mohammadzadeh","year":"2012","journal-title":"Cell Stress Chaperones"},{"key":"2021113011161361600_B39","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase iii randomized trials: rise and ride","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"2021113011161361600_B40","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","article-title":"Different signal transduction properties of kdr and flt1, two receptors for vascular endothelial growth factor","volume":"269","author":"Waltenberger","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2021113011161361600_B41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ars.2013.5244","article-title":"Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1 and oxidative stress","volume":"20","author":"Lankhorst","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"2021113011161361600_B42","first-page":"H1054","article-title":"Vegf upregulates ecnos message, protein, and no production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am. J. Physiol."},{"key":"2021113011161361600_B43","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"The viva trial: vascular endothelial growth factor in ischemia for vascular angiogenesis","volume":"107","author":"Henry","year":"2003","journal-title":"Circulation"},{"key":"2021113011161361600_B44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1067\/mhj.2001.118471","article-title":"Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease","volume":"142","author":"Henry","year":"2001","journal-title":"Am. Heart J."},{"key":"2021113011161361600_B45","doi-asserted-by":"publisher","first-page":"C695","DOI":"10.1152\/ajpcell.00322.2010","article-title":"Regulation of vegf-induced endothelial cell migration by mitochondrial reactive oxygen species","volume":"301","author":"Wang","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011161361600_B46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2013-09-512749","article-title":"Oxidative stress in angiogenesis and vascular disease","volume":"123","author":"Kim","year":"2014","journal-title":"Blood"},{"key":"2021113011161361600_B47","doi-asserted-by":"publisher","first-page":"C749","DOI":"10.1152\/ajpcell.00346.2016","article-title":"Ros-induced ros release orchestrated by nox4, nox2, and mitochondria in vegf signaling and angiogenesis","volume":"312","author":"Kim","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011161361600_B48","doi-asserted-by":"publisher","first-page":"17690","DOI":"10.1002\/jcp.28395","article-title":"Vegf-a promotes angiogenesis after acute myocardial infarction through increasing ros production and enhancing er stress-mediated autophagy","volume":"234","author":"Zou","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"2021113011161361600_B49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/blood-2004-04-1519","article-title":"Vascular endothelial growth factor regulation of weibel-palade-body exocytosis","author":"Matsushita","year":"2005","journal-title":"Blood"},{"key":"2021113011161361600_B50","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/01.ATV.0000209501.56852.6c","article-title":"Dynamics and plasticity of weibel-palade bodies in endothelial cells","volume":"26","author":"Rondaij","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011161361600_B51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.1991.tb43697.x","article-title":"Molecular biology of von willebrand factor","volume":"614","author":"Sadler","year":"1991","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2021113011161361600_B52","doi-asserted-by":"publisher","first-page":"23217","DOI":"10.1074\/jbc.M109.019679","article-title":"Vascular endothelial growth factor (vegf) receptor-2 tyrosine 1175 signalling controls vegf-induced von willebrand factor release from endothelial cells via phospholipase c-gamma 1- and protein kinase a-dependent pathways","volume":"284","author":"Xiong","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2021113011161361600_B53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/07853898909149179","article-title":"Mediators and the anti-thrombotic properties of the vascular endothelium","volume":"21","author":"Botting","year":"1989","journal-title":"Ann. Med."},{"key":"2021113011161361600_B54","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1111\/j.1538-7836.2008.03138.x","article-title":"Protein kinase c-delta mediates von willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (vegf) but not histamine","volume":"6","author":"Lorenzi","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"2021113011161361600_B55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.tcm.2005.09.005","article-title":"Regulation of weibel-palade body exocytosis","volume":"15","author":"Lowenstein","year":"2005","journal-title":"Trends Cardiovasc. Med."},{"key":"2021113011161361600_B56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1113\/expphysiol.2007.038588","article-title":"Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium","volume":"93","author":"Mitchell","year":"2008","journal-title":"Exp. Physiol."},{"key":"2021113011161361600_B57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/01.CIR.97.1.99","article-title":"Vascular endothelial growth factor\/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin","volume":"97","author":"Murohara","year":"1998","journal-title":"Circulation"},{"key":"2021113011161361600_B58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0014-5793(97)01481-6","article-title":"Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase a2 in endothelial cells via p42\/p44 mitogen-activated protein kinase","volume":"420","author":"Wheeler-Jones","year":"1997","journal-title":"FEBS Lett."},{"key":"2021113011161361600_B59","first-page":"635","article-title":"Vegf non-angiogenic functions in adult organ homeostasis: therapeutic implications","volume":"2011","author":"Luo","journal-title":"J. Mol. Med."},{"key":"2021113011161361600_B60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0092-8674(03)00803-1","article-title":"Nitric oxide regulates exocytosis by s-nitrosylation of n-ethylmaleimide-sensitive factor","volume":"115","author":"Matsushita","year":"2003","journal-title":"Cell"},{"key":"2021113011161361600_B61","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1161\/CIRCULATIONAHA.108.782482","article-title":"Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients","volume":"119","author":"Giannarelli","year":"2009","journal-title":"Circulation"},{"key":"2021113011161361600_B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.047","article-title":"Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans","volume":"51","author":"Gudmundsd\u00f3ttir","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011161361600_B63","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.6.1314","article-title":"Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization","volume":"35","author":"Honing","year":"2000","journal-title":"Hypertension"},{"key":"2021113011161361600_B64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1160\/TH05-02-0092","article-title":"Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of galphaq, plc-beta, ip3 and 5, 6-epoxyeicosatrienoic acid","volume":"97","author":"Muldowney","year":"2007","journal-title":"Thromb. Haemost."},{"key":"2021113011161361600_B65","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1161\/01.CIR.102.18.2190","article-title":"Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through b2 receptor-dependent, no synthase-independent, and cyclooxygenase-independent pathway","volume":"102","author":"Brown","year":"2000","journal-title":"Circulation"},{"key":"2021113011161361600_B66","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1161\/01.ATV.0000189309.05924.88","article-title":"Stimulated tissue plasminogen activator release as a marker of endothelial function in humans","volume":"25","author":"Oliver","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011161361600_B67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of vegf-induced vascular permeability","volume":"437","author":"Weis","year":"2005","journal-title":"Nature"},{"key":"2021113011161361600_B68","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/cvr\/cvq105","article-title":"Vascular endothelial growth factors and vascular permeability","volume":"87","author":"Bates","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"2021113011161361600_B69","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.110.957332","article-title":"Vascular endothelial growth factor-b acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation","volume":"122","author":"Bry","year":"2010","journal-title":"Circulation"},{"key":"2021113011161361600_B70","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (vegf) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int."},{"key":"2021113011161361600_B71","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1186\/ar582","article-title":"Vegf and imaging of vessels in rheumatoid arthritis","volume":"4","author":"Taylor","year":"2002","journal-title":"Arthritis Res."},{"key":"2021113011161361600_B72","first-page":"247","article-title":"Vegf involvement in psoriasis","volume":"88","author":"Marina","year":"2015","journal-title":"Clujul. Med."},{"key":"2021113011161361600_B73","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1101\/gad.1102703","article-title":"Transcriptional regulation by calcium, calcineurin, and nfat","volume":"17","author":"Hogan","year":"2003","journal-title":"Genes Dev."},{"key":"2021113011161361600_B74","doi-asserted-by":"publisher","first-page":"7020","DOI":"10.1167\/iovs.13-12183","article-title":"The role of the nfat signaling pathway in retinal neovascularization","volume":"54","author":"Bretz","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021113011161361600_B75","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nm.1877","article-title":"Suppressed nfat-dependent vegfr1 expression and constitutive vegfr2 signaling in infantile hemangioma","volume":"14","author":"Jinnin","year":"2008","journal-title":"Nat. Med."},{"key":"2021113011161361600_B76","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1128\/MCB.00494-15","article-title":"C\/ebpbeta and nuclear factor of activated t cells differentially regulate adamts-1 induction by stimuli associated with vascular remodeling","volume":"35","author":"Oller","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"2021113011161361600_B77","first-page":"CD007893","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"2021113011161361600_B78","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0025-6196(12)65772-3","article-title":"Cyclosporine-induced hypertension after transplantation","volume":"69","author":"Textor","year":"1994","journal-title":"Mayo Clin. Proc."},{"key":"2021113011161361600_B79","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ki.1985.196","article-title":"Effect of cyclosporine administration on renal hemodynamics in conscious rats","volume":"28","author":"Murray","year":"1985","journal-title":"Kidney Int."},{"key":"2021113011161361600_B80","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/01.CIR.88.3.1101","article-title":"Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation","volume":"88","author":"Kaye","year":"1993","journal-title":"Circulation"},{"key":"2021113011161361600_B81","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1172\/JCI117222","article-title":"Vascular mechanisms of cyclosporin-induced hypertension in the rat","volume":"93","author":"Roullet","year":"1994","journal-title":"J. Clin. Invest."},{"key":"2021113011161361600_B82","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1046\/j.1523-1755.2000.00937.x","article-title":"Endothelial dysfunction in renal transplant recipients maintained on cyclosporine","volume":"57","author":"Morris","year":"2000","journal-title":"Kidney Int."},{"key":"2021113011161361600_B83","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/01.HYP.25.4.764","article-title":"Cyclosporin a inhibits nitric oxide synthase induction in vascular smooth muscle cells","volume":"25","author":"Marumo","year":"1995","journal-title":"Hypertension"},{"key":"2021113011161361600_B84","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0002-9343(88)80331-0","article-title":"Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent","volume":"85","author":"Curtis","year":"1988","journal-title":"Am. J. Med."},{"key":"2021113011161361600_B85","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1073\/pnas.82.23.8222","article-title":"Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats","volume":"82","author":"Moss","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011161361600_B86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells","volume":"9","author":"Sharma","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2021113011161361600_B87","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"Vegfr (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"2021113011161361600_B88","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1097\/HJH.0b013e3283309b59","article-title":"Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects","volume":"27","author":"Kappers","year":"2009","journal-title":"J. Hypertens."},{"key":"2021113011161361600_B89","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/HJH.0b013e32835c1d1b","article-title":"Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1","volume":"31","author":"Lankhorst","year":"2013","journal-title":"J. Hypertens."},{"key":"2021113011161361600_B90","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"2021113011161361600_B91","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0008-6363(98)00228-4","article-title":"Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells","volume":"41","author":"Bouloumi\u00e9","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"2021113011161361600_B92","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"2021113011161361600_B93","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1006\/bbrc.1998.9719","article-title":"Vegf-a induces expression of enos and inos in endothelial cells via vegf receptor-2 (kdr)","volume":"252","author":"Kroll","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011161361600_B94","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2014.11.010","article-title":"Etiology of angiogenesis inhibition-related hypertension","volume":"21","author":"Lankhorst","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"2021113011161361600_B95","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinomas patients receiving vascular endothelial growth factor signalling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"2021113011161361600_B96","doi-asserted-by":"publisher","first-page":"33057","DOI":"10.1074\/jbc.274.46.33057","article-title":"Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a hdr\/flk-1 receptor and a protein kinase c signalling pathway","volume":"274","author":"Shen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021113011161361600_B97","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz260","article-title":"Selective eta versus dual eta\/b receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in wky rats","volume":"116","author":"Mirabito Colafella","journal-title":"Cardiovasc. Res."},{"key":"2021113011161361600_B98","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"2021113011161361600_B99","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann. Oncol."},{"key":"2021113011161361600_B100","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jacc.2012.02.053","article-title":"Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer","volume":"60","author":"Belcik","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011161361600_B101","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc. Med."},{"key":"2021113011161361600_B102","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz021","article-title":"Microparticles from vegf inhibitor-treated cancer patients mediate endothelial cell injury","volume":"115","author":"Neves","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"2021113011161361600_B103","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"2021113011161361600_B104","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1097\/HJH.0000000000000662","article-title":"Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension","volume":"33","author":"Thijs","year":"2015","journal-title":"J. Hypertens."},{"key":"2021113011161361600_B105","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"2021113011161361600_B106","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2021113011161361600_B107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2040-7378-5-7","article-title":"Anti-vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study","volume":"5","author":"Reimann","year":"2013","journal-title":"Exp. Transl. Stroke Med."},{"key":"2021113011161361600_B108","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1536\/ihj.16-537","article-title":"Bevacizumab-related microvascular angina and its management with nicorandil","volume":"58","author":"Katoh","year":"2017","journal-title":"Int. Heart J."},{"key":"2021113011161361600_B109","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1158\/1078-0432.CCR-13-2056","article-title":"Aflibercept and its role in the treatment of colorectal cancer\u2013letter","volume":"19","author":"Sinicrope","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2021113011161361600_B110","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/JTO.0b013e3181e2f7fb","article-title":"A multicenter, phase 2 study of vascular endothelial growth factor trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung","volume":"5","author":"Leighl","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"2021113011161361600_B111","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic vegf inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis\u2013implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021113011161361600_B112","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/hrt.2004.053991","article-title":"Endothelin antagonism in pulmonary hypertension, heart failure, and beyond","volume":"91","author":"Attin\u00e0","year":"2005","journal-title":"Heart"},{"key":"2021113011161361600_B113","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11906-013-0380-1","article-title":"Endothelin antagonism and its role in the treatment of hypertension","volume":"15","author":"Moorhouse","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"2021113011161361600_B114","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"2021113011161361600_B115","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cardiores.2007.02.015","article-title":"Nadph oxidase mediates angiotensin ii-induced endothelin-1 expression in vascular adventitial fibroblasts","volume":"75","author":"An","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"2021113011161361600_B116","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1054-8807(01)00095-3","article-title":"Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells","volume":"10","author":"Ruef","year":"2001","journal-title":"Cardiovasc. Pathol."},{"key":"2021113011161361600_B117","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"2010","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2021113011161361600_B118","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1161\/HYPERTENSIONAHA.108.117366","article-title":"Role of endothelin-1 in clinical hypertension: 20 years on","volume":"52","author":"Dhaun","year":"2008","journal-title":"Hypertension"},{"key":"2021113011161361600_B119","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0014-2999(98)00806-1","article-title":"Effects of endo-genous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells","volume":"364","author":"Mitsutomi","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"2021113011161361600_B120","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"2021113011161361600_B121","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with teletinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2021113011161361600_B122","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (vegf) signaling in cancer causes loss of endothelial fenestrations, regression of tumour vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am. J. Pathol."},{"key":"2021113011161361600_B123","doi-asserted-by":"publisher","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque","year":"2014","journal-title":"PLoS ONE"},{"key":"2021113011161361600_B124","doi-asserted-by":"publisher","first-page":"C1375","DOI":"10.1152\/ajpcell.2001.280.6.C1375","article-title":"Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor","volume":"280","author":"Zachary","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011161361600_B125","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"2021113011161361600_B126","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm1428","article-title":"Vegf modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis","volume":"12","author":"Tam","year":"2006","journal-title":"Nat. Med."},{"key":"2021113011161361600_B127","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1055\/s-0038-1657647","article-title":"Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm","volume":"78","author":"Jern","year":"1997","journal-title":"Thromb. Haemost."},{"key":"2021113011161361600_B128","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1161\/01.ATV.0000189309.05924.88","article-title":"Stimulated tpa release as a marker of endothelial function in humans","volume":"25","author":"Oliver","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011161361600_B129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0037-1616107","article-title":"Synergistic induction of t-pa by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-pa to weibel-palade bodies in bovine microvascular endothelial cells","volume":"86","author":"Pepper","year":"2001","journal-title":"Thromb. Haemost."},{"key":"2021113011161361600_B130","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-015-0418-x","article-title":"Bevacizumab promotes venous thromboembolism through the induction of pai-1 in a mouse xenograft model of human lung carcinoma","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer"},{"key":"2021113011161361600_B131","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.semcdb.2012.05.003","article-title":"Redox balance dynamically regulates vascular growth and remodelling","volume":"23","author":"Bir","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"2021113011161361600_B132","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1023\/B:MCBI.0000044378.09409.b5","article-title":"Reactive oxygen species as mediators of angiogenesis signalling: role of nad(p)h oxidase","volume":"264","author":"Ushio-Fukai","year":"2004","journal-title":"Mol. Cell. Biochem."},{"key":"2021113011161361600_B133","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1089\/ars.2007.1989","article-title":"Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension","volume":"10","author":"Schulz","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"2021113011161361600_B134","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1042\/CS20120309","article-title":"Microparticles: biomarkers and beyond","volume":"124","author":"Burger","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011161361600_B135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102584","article-title":"Involvement of extracellular vesicles in vascular-related functions in cancer progression and metastasis","volume":"20","author":"Kikuchi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011161361600_B136","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1161\/CIRCRESAHA.117.310752","article-title":"Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology","volume":"120","author":"Jansen","year":"2017","journal-title":"Circ. Res."},{"key":"2021113011161361600_B137","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021113011161361600_B138","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1038\/s41598-017-05002-y","article-title":"Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity","volume":"7","author":"Schillaci","year":"2017","journal-title":"Sci. Rep."},{"key":"2021113011161361600_B139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051362","article-title":"The janus face of vegf in stroke","volume":"19","author":"Geiseler","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011161361600_B140","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"2021113011161361600_B141","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"2021113011161361600_B142","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann. Oncol."},{"key":"2021113011161361600_B143","doi-asserted-by":"publisher","first-page":"e102484","DOI":"10.1371\/journal.pone.0102484","article-title":"Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis","volume":"9","author":"Zuo","year":"2014","journal-title":"PLoS ONE"},{"key":"2021113011161361600_B144","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12931-017-0602-1","article-title":"Vegf isoforms have differential effects on permeability of human pulmonary microvascular endothelial cells","volume":"18","author":"Ourradi","year":"2017","journal-title":"Respir. Res."},{"key":"2021113011161361600_B145","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"2021113011161361600_B146","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/JTO.0000000000000434","article-title":"Phase ii trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating egfr gene mutations: the Okayama Lung Cancer Study Group Trial 1001","volume":"10","author":"Ichihara","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"2021113011161361600_B147","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11864-019-0617-6","article-title":"The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer","volume":"20","author":"Perdrizet","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"2021113011161361600_B148","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40264-017-0596-0","article-title":"Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (jo25567): updated safety results","volume":"41","author":"Kato","year":"2018","journal-title":"Drug Saf."},{"key":"2021113011161361600_B149","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with egfr-positive advanced non-squamous non-small-cell lung cancer (nej026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"2021113011161361600_B150","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1527-3466.2007.00018.x","article-title":"Role of poly(adp-ribose) polymerase 1 (parp-1) in cardiovascular diseases: the therapeutic potential of parp inhibitors","volume":"25","author":"Pacher","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"2021113011161361600_B151","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of parylation in DNA damage repair pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2021113011161361600_B152","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.119.13861","article-title":"Crosstalk between vascular redox and calcium signaling in hypertension involves trpm2 (transient receptor potential melastatin 2) cation channel","volume":"75","author":"Alves-Lopes","year":"2020","journal-title":"Hypertension"},{"key":"2021113011161361600_B153","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1038\/s41598-019-40330-1","article-title":"Trpm2 ion channel promotes gastric cancer migration, invasion and tumor growth through the akt signaling pathway","volume":"9","author":"Almasi","year":"2019","journal-title":"Sci. Rep."},{"key":"2021113011161361600_B154","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2021113011161361600_B155","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00280-019-03917-z","article-title":"A phase i study of the parp inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: Nsgo avanova1\/engot-ov24","volume":"84","author":"Mirza","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2021113011161361600_B156","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.2147\/CMAR.S200524","article-title":"Current status and future prospects of parp inhibitor clinical trials in ovarian cancer","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"2021113011161361600_B157","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021113011161361600_B158","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"key":"2021113011161361600_B159","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase ii study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"key":"2021113011161361600_B160","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060155","article-title":"Targeted tumor therapy remixed-an update on the use of small-molecule drugs in combination therapies","volume":"10","author":"Gatzka","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2021113011161361600_B161","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/cvr\/cvn018","article-title":"Differential effects of parp inhibition on vascular cell survival and acat-1 expression favouring atherosclerotic plaque stability","volume":"78","author":"Hans","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"2021113011161361600_B162","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"2021113011161361600_B163","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040930","article-title":"Angiogenesis and immunity in renal carcinoma: can we turn an unhappy relationship into a happy marriage?","volume":"9","author":"Mennitto","year":"2020","journal-title":"J. Clin. Med."},{"key":"2021113011161361600_B164","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11864-019-0638-1","article-title":"The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions","volume":"20","author":"Salgia","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"2021113011161361600_B165","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/1078155219854797","article-title":"Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - a retrospective study","volume":"26","author":"Jammal","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2021113011161361600_B166","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2016.09.002","article-title":"Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy","volume":"50","author":"Calvo","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"2021113011161361600_B167","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous nsclc","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021113011161361600_B168","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/CAD.0b013e32834ee2b1","article-title":"Sorafenib, but not sunitinib, induces regulatory t cells in the peripheral blood of patients with metastatic renal cell carcinoma","volume":"23","author":"Florcken","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2021113011161361600_B169","doi-asserted-by":"publisher","first-page":"16334","DOI":"10.1074\/jbc.M112.437962","article-title":"Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors","volume":"288","author":"Stehle","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2021113011161361600_B170","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1470-2045(19)30085-3","article-title":"Bevacizumab in egfr-positive nsclc: time to change first-line treatment?","volume":"20","author":"Yang","year":"2019","journal-title":"Lancet Oncol."},{"key":"2021113011161361600_B171","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front. Immunol."},{"key":"2021113011161361600_B172","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1681\/ASN.2011111116","article-title":"Vasculitis is an antiangiogenic state","volume":"23","author":"Stillman","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011161361600_B173","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1681\/ASN.2010080858","article-title":"Elevated soluble flt1 inhibits endothelial repair in pr3-anca-associated vasculitis","volume":"23","author":"Le Roux","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011161361600_B174","first-page":"366","article-title":"Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in arpe-19 cells","volume":"10","author":"Chu","year":"2017","journal-title":"Int. J. Ophthalmol."},{"key":"2021113011161361600_B175","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/IAE.0b013e3182979df6","article-title":"Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy","volume":"34","author":"Suzuki","year":"2014","journal-title":"Retina"},{"key":"2021113011161361600_B176","doi-asserted-by":"publisher","first-page":"e1457598","DOI":"10.1080\/2162402X.2018.1457598","article-title":"Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab","volume":"7","author":"Jabeen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2021113011161361600_B177","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/nm.3333","article-title":"Il-17 mediates resistance to anti-vegf therapy","volume":"19","author":"Maniati","year":"2013","journal-title":"Nat. Med."},{"key":"2021113011161361600_B178","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the pd-l1 inhibitor, durvalumab, in combination with a parp inhibitor, olaparib, and a vegfr1-3 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"2021113011161361600_B179","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"2021113011161361600_B180","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2021113011161361600_B181","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"2021113011161361600_B182","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Written on behalf of the AMEALCCG. Evaluation of rare but severe immune related adverse effects in pd-1 and pd-l1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"2021113011161361600_B183","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021113011161361600_B184","first-page":"1758835919875549","article-title":"The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma","volume":"11","author":"Marco","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2021113011161361600_B185","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"2021113011161361600_B186","doi-asserted-by":"publisher","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011161361600_B187","doi-asserted-by":"publisher","first-page":"E970","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011161361600_B188","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072606","article-title":"The epigenetic profile of tumor endothelial cells. Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression","volume":"21","author":"Ciesielski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011161361600_B189","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080268","article-title":"The methylation status of the epigenome: its emerging role in the regulation of tumor angiogenesis and tumor growth, and potential for drug targeting","volume":"10","author":"Pirola","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2021113011161361600_B190","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cbpa.2019.11.009","article-title":"Drugging histone methyltransferases in cancer","volume":"56","author":"Richart","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2021113011161361600_B191","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011161361600_B192","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2016.70.5350","article-title":"Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies","volume":"35","author":"Aggarwal","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2021113011161361600_B193","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1158\/0008-5472.CAN-12-3231","article-title":"Inhibition of histone demethylase jmjd1a improves anti-angiogenic therapy and reduces tumor-associated macrophages","volume":"73","author":"Osawa","year":"2013","journal-title":"Cancer Res."},{"key":"2021113011161361600_B194","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00280-012-1911-1","article-title":"Phase I study of bevacizumab, everolimus, and panobinostat (lbh-589) in advanced solid tumors","volume":"70","author":"Strickler","year":"2012","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/18\/2503\/894143\/cs-2020-0308c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/18\/2503\/894143\/cs-2020-0308c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T07:14:44Z","timestamp":1638256484000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/134\/18\/2503\/226546\/Vascular-toxicity-associated-with-anti-angiogenic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":194,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9,30]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20200308","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9]]}}}